

Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC (Text with EEA relevance) (revoked)

CHAPTER VI

CLINICAL EVALUATION AND CLINICAL INVESTIGATIONS

Article 67

Additional national measures

.....

Textual Amendments applied to the whole legislation

- F1** Regulation revoked (31.12.2020) by [The Medical Devices Regulations 2002](#) (S.I. 2002/618), **reg. 40** (with savings and transitional provisions for N.I. in [reg. 3ZA](#)) (as amended by [S.I. 2019/791](#), regs. 1(1), **3(7)**) and by [S.I. 2020/1478](#), regs. 1(3), **Sch. 2 para. 2**; and as amended (27.7.2021) by [The Medical Devices \(Northern Ireland Protocol\) Regulations 2021](#) (S.I. 2021/905), regs. 1(2), 4, **32**; 2020 c. 1, **Sch. 5 para. 1(1)**)

Status:

This version of this provision no longer has effect.

Changes to legislation:

There are currently no known outstanding effects for the Regulation (EU) 2017/745 of the European Parliament and of the Council, Article 67.